DA
ABBV icon

Detalus Advisors’s AbbVie ABBV Stock Holding History

Detalus Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.62M Sell
14,381
-275
-2% -$59.2K 0.71% 32
2026
Q1 		$3.19M Sell
14,656
-63
-0.4% -$14K 0.73% 30
2025
Q4 		$3.36M Sell
14,719
-7
-0% -$1.59K 0.82% 25
2025
Q3 		$3.41M Buy
14,726
+25
+0.2% +$5.09K 0.88% 24
2025
Q2 		$2.73M Buy
14,701
+2
+0% +$372 0.79% 28
2025
Q1 		$3.08M Buy
14,699
+65
+0.4% +$12.6K 0.97% 25
2024
Q4 		$2.6M Buy
14,634
+36
+0.2% +$6.62K 0.86% 25
2024
Q3 		$2.88M Buy
14,598
+44
+0.3% +$8.21K 0.96% 21
2024
Q2 		$2.5M Sell
14,554
-1,451
-9% -$240K 0.86% 22
2024
Q1 		$2.91M Sell
16,005
-124
-0.8% -$21.4K 1.04% 22
2023
Q4 		$2.5M Sell
16,129
-400
-2% -$58.3K 1% 21
2023
Q3 		$2.46M Sell
16,529
-200
-1% -$29.4K 1.15% 17
2023
Q2 		$2.25M Buy
16,729
+224
+1% +$32.8K 1.01% 19
2023
Q1 		$2.63M Sell
16,505
-994
-6% -$152K 1.26% 17
2022
Q4 		$2.83M Buy
17,499
+13,785
+371% +$2.11M 1.38% 16
2022
Q3 		$498K Sell
3,714
-100
-3% -$14.3K 0.3% 66
2022
Q2 		$584K Hold
3,814
– – 0.34% 56
2022
Q1 		$618K Sell
3,814
-2,400
-39% -$349K 0.33% 52
2021
Q4 		$841K Sell
6,214
-90
-1% -$10.6K 0.4% 41
2021
Q3 		$680K Buy
6,304
+350
+6% +$40K 0.35% 50
2021
Q2 		$671K Buy
+5,954
New +$671K 0.36% 50
2020
Q3 		– Sell
-2,474
Closed -$243K – 90
2020
Q2 		$243K Buy
+2,474
New +$218K 0.19% 80
2020
Q1 		– Sell
-2,425
Closed -$215K – 87
2019
Q4 		$215K Buy
+2,425
New +$201K 0.16% 93

Other funds holding ABBV

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Detalus Advisors's ABBV Position: Q2 2026 in Review

Detalus Advisors reduced its AbbVie (ABBV) stake by 1.9% in Q2 2026, selling an estimated $59.2K and leaving 14,381 shares worth $3.62M. The position accounts for 0.71% of the portfolio, ranked #32.

Detalus Advisors first reported a position in ABBV in Q4 2019 and has held it in 23 quarters since. 2,010 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Detalus Advisors held 14,381 shares of AbbVie worth $3.62M as of Q2 2026.
  • Detalus Advisors sold 275 AbbVie shares in Q2 2026, an estimated $59.2K.
  • AbbVie made up 0.71% of Detalus Advisors's portfolio in Q2 2026, its #32 holding.
  • Detalus Advisors first reported a position in AbbVie in Q4 2019 and has held it in 23 quarters since.
  • 2,010 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Detalus Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.